articleCirculationJun 13, 2006BRONZE OA

Prevalence, Predictors, and Outcomes of Premature Discontinuation of Thienopyridine Therapy After Drug-Eluting Stent Placement

University of Colorado Hospital · Barnes-Jewish Hospital · +6 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

BACKGROUND: Although drug-eluting stents (DES) significantly reduce restenosis, they require 3 to 6 months of thienopyridine therapy to prevent stent thrombosis. The rate and consequences of prematurely discontinuing thienopyridine therapy after DES placement for acute myocardial infarction (MI) are unknown. METHODS AND RESULTS: We used prospectively collected data from a 19-center study of MI patients to examine the prevalence and predictors of thienopyridine discontinuation 30 days after DES treatment. We then compared the mortality and cardiac hospitalization rates for the next 11 months between those who stopped and those who continued thienopyridine therapy. Among 500 DES-treated MI patients who were…

Citation impact

858
total citations
FWCI
98.63
Percentile
100%
References
40
Citations per year

Authors

12

Topics & keywords

Keywords
  • Medicine
  • Thienopyridine
  • Discontinuation
  • Drug
  • Internal medicine
  • Drug-eluting stent
  • Cardiology
  • Intensive care medicine
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.